肝胆肿瘤分子诊断临床应用专家共识(2024年版)  

Expert consensus for clinical application of molecular diagnosis on hepatobiliary tumors(2024 edition)

作　　者：中国研究型医院学会分子诊断医学专业委员会 中国老年学和老年医学会转化医学分会 陆荫英 程家敏 郎韧[4] 彭涛 Society for Molecular Diagnosis,Chinese Research Hospital Association;Translational Medicine Branch of China Association of Gerontology and Geriatrics;Lu Yinying(不详;the Fifth Medical Center of PLA General Hospital,Beijing 100039,China)

机构地区：[1]不详 [2]中国人民解放军总医院第五医学中心,北京100039 [3]中国人民解放军总医院第五医学中心 [4]首都医科大学附属北京朝阳医院 [5]广西医科大学第一附属医院

出　　处：《中华肝脏病杂志》2024年第10期872-882,共11页Chinese Journal of Hepatology

基　　金：国家自然科学基金面上项目(82272956)。

摘　　要：分子诊断对于肝胆肿瘤的临床诊疗有重要意义。专家组在2020年首次发布了《肝胆肿瘤分子诊断临床应用专家共识》,该共识的推出推动了分子诊断技术在肝胆肿瘤临床工作中的规范化应用,提高了临床医师对肝胆肿瘤的诊断与治疗能力。近年,有关肝胆肿瘤的研究逐渐展开,新的研究结果不断公布。专家组结合最新的研究进展在原有共识的基础上更新了共识,聚焦于肝胆肿瘤的靶向和免疫治疗的分子标志物的检测,以期为临床医师在治疗决策时提供参考,使患者最大程度获益。Molecular diagnosis is of enormous significance for the clinical diagnosis and treatment of hepatobiliary tumors.The expert group first released the"Expert Consensus for Clinical Application of Molecular Diagnosis on Hepatobiliary Tumors"in 2020.The introduction of this consensus has promoted the standardized application of molecular diagnostic technology in the clinical work of hepatobiliary tumors and improved the diagnosis and treatment capabilities of clinical physicians for hepatobiliary tumors.Research on hepatobiliary tumors has gradually been carried out in recent years,with the continuous publication of new research results.Hence,the expert group updated this consensus on the basis of the latest research progress,the original consensus,with a focus on the detection of molecular markers for targeted and immunotherapy of hepatobiliary tumors,in order to provide a reference for clinical physicians in treatment decisions and maximize the benefits for patients.

关 键 词：肝细胞癌 胆道 肿瘤 诊断 靶向治疗 免疫治疗 标志物 专家共识 

分 类 号：R735.7[医药卫生—肿瘤]